MONOPAR THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6499 USD | -1.26% |
|
+2.83% | +91.03% |
| 04-16 | Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct | MT |
| 04-16 | Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.49M 15.68M |
|---|---|---|---|---|---|
| Net income 2024 * | -9M -12.28M | Net income 2025 * | -10M -13.64M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.13
x | P/E ratio 2025 * |
-1.46
x | Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.65% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.26% | ||
| 1 week | +2.83% | ||
| Current month | -4.57% | ||
| 1 month | -4.29% | ||
| 3 months | +80.53% | ||
| 6 months | +60.87% | ||
| Current year | +91.03% |
1 week
0.61
0.68
1 month
0.500.85
Current year
0.311.73
1 year
0.271.75
3 years
0.276.98
5 years
0.2748.00
10 years
0.2748.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 40 | 14-11-30 | |
Kim Tsuchimoto
DFI | Director of Finance/CFO | 61 | 15-05-31 |
Laura Kelly
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brown
BRD | Director/Board Member | 67 | 14-11-30 |
Arthur Klausner
BRD | Director/Board Member | 64 | 17-07-31 |
Kim Tsuchimoto
DFI | Director of Finance/CFO | 61 | 15-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.6499 | -1.26% | 8 154 |
| 24-04-26 | 0.6582 | +4.89% | 35,008 |
| 24-04-25 | 0.6275 | -4.49% | 58,241 |
| 24-04-24 | 0.657 | +1.08% | 39,446 |
| 24-04-23 | 0.65 | +2.85% | 85,910 |
Delayed Quote Nasdaq, April 29, 2024 at 12:04 pm
More quotes
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6582
USD
Average target price
3.363
USD
Spread / Average Target
+410.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +91.03% | 11.49M | |
| +2.67% | 42.75B | |
| +47.70% | 41.61B | |
| +12.22% | 41.34B | |
| -8.83% | 26.59B | |
| +8.30% | 25.49B | |
| -22.52% | 18.12B | |
| +31.20% | 12.24B | |
| -1.48% | 11.76B | |
| +9.05% | 11B |
- Stock Market
- Equities
- MNPR Stock
